EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A Review

Meave Phipps iD, Gerald S Falchook iD

Journal of Immunotherapy and Precision Oncology · 01.05.2025 · 8 (2) · 153-160

DOI: 10.36401/jipo-24-34 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Immunotherapy and Precision Oncology, online erschienen am 10.04.2025. Verfasst von Meave Phipps und 1 weiteren Autor:innen. Beteiligte Einrichtung: Sarah Cannon Research Institute at HealthONE, Denver, CO, USA. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B7 homolog 4 (B7-H4) is a transmembrane protein found on immune cells and is frequently overexpressed in various solid tumors, making it a promising target for cancer therapy. B7-H4–directed agents, particularly antibody-drug conjugates (ADCs) like puxitatug samrotecan (AZD8205), felmetatug vedotin (SGN-B7H4V), and GSK5733584, have demonstrated early clinical activity with promising response rates in triple-negative breast cancer (TNBC). Combination strategies, such as ADCs with anti–PD-1 or PARP inhibitor therapies, have also shown enhanced tumor regression in preclinical models and are the subject of several ongoing clinical trials. This review highlights the current landscape of B7-H4–targeted agents, their progress in clinical trials, and the potential for combination approaches to improve outcomes in B7-H4–expressing cancers.

Schlagwörter

Stichwörter der Autor:innen

B7-H4cancerclinical trials

Autor:innen und Institutionen

  • Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.

ORCID-Profile: Meave Phipps, Gerald S Falchook

Zitieren

APA

Phipps, M., & Falchook, G. S. (2025). B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A Review. Journal of Immunotherapy and Precision Oncology, 8(2), 153-160. https://doi.org/10.36401/jipo-24-34

Vancouver

Phipps M, Falchook GS. B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A Review. Journal of Immunotherapy and Precision Oncology. 2025;8(2):153-160. doi:10.36401/jipo-24-34

BibTeX
@article{Phipps2025,
  author = {Phipps, Meave and Falchook, Gerald S},
  title = {B7 Homolog 4 (B7-H4)-Directed Agents in Oncology Clinical Trials: A Review},
  journal = {Journal of Immunotherapy and Precision Oncology},
  year = {2025},
  volume = {8},
  number = {2},
  pages = {153--160},
  doi = {10.36401/jipo-24-34}
}
Kostenlos starten →